VBI Vaccines Receives US FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Inc. announced that the US FDA granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma.
[VBI Vaccines Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News